Oxford BioTherapeutics Adds New Board Member
This article was originally published in Scrip
Oxford BioTherapeutics has appointed Shawn Tomasello to its board of directors. Previously she was chief commercial officer of Pharmacyclics and before this she was president of the Americas, hematology and oncology for Celgene Corp. Previously, Tomasello was national director of hematology for Rituxan at Genetech.
Register for our free email digests: